Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …

Abstract The Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) was
developed in the 1980s to assess the level of cognitive dysfunction in Alzheimer's disease …

Background A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ)
peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being …

Experimental sleep-wake disruption in rodents and humans causally modulates β-amyloid
(Aβ) dynamics (eg,[1–3]). This leads to the hypothesis that, beyond cross-sectional …

As the field begins to test the concept of a" preclinical" stage of neurodegenerative disease,
when the pathophysiological process has begun in the brain, but clinical symptoms are not …

Importance As Alzheimer disease (AD) research moves to intervene in presymptomatic
phases of the disease, we must develop outcome measures sensitive to the earliest disease …

Positron emission tomography (PET) of brain amyloid β is a technology that is becoming
more available, but its clinical utility in medical practice requires careful definition. To …

Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for
which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of …

The concept of mild cognitive impairment (MCI) as an intermediate state between normal
cognition and dementia entered into the vernacular of geriatric medicine more than 30 years …

The accurate measurement of β-amyloid (Aβ) change using amyloid PET imaging is
important for Alzheimer disease research and clinical trials but poses several unique …